New FDA Drug Approvals Reach 21-Year High in 2017

But average returns on research and development have fallen

U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light—more than double the previous year—while the figure also rose in the European Union, according to a Reuters report.

The E.U. recommended 92 new drugs, including generics, up from 81, and China laid out plans to speed approvals in what is now the world’s second-biggest market behind the United States.

Yet the world’s biggest drug-makers saw average returns on their research and development spending fall, reflecting more competitive pressures and the growing share of new products now coming from younger biotech companies. Consultancy Deloitte said last month that projected returns at 12 of the world’s top drug-makers were at an eight-year low of only 3.2%, Reuters reported.

Many of the drugs receiving a green light in 2017 were for rare diseases and subtypes of cancer, which often target very small populations, although they can cost hundreds of thousands of dollars.

Significantly, the U.S. drug tally of 46 does not include the first of a new wave of cell and gene therapies from Novartis, Gilead Sciences, and Spark Therapeutics that were approved in 2017 under a separate category. FDA Commissioner Scott Gottlieb has hailed these products as “a whole new scientific paradigm for the treatment of serious diseases.” However, there is debate as to how cash-strapped health care systems will pay for them.

Under Gottlieb, the FDA has taken advantage of policy changes implemented in recent years to accelerate the drug approval process. Procedures such as the agency’s “breakthrough therapy” designation have cut review times and helped to stimulate competition by adding multiple new drugs that often work in a similar way.

Pfizer and Merck’s new diabetes drug Steglatro (ertugliflozin), for example, was the fourth product of its kind to win a green light in the United States, while Novo Nordisk’s Ozempic (semaglutide) was the sixth of its type. Both were approved in December.

In cancer, AstraZeneca’s Imfinzi (durvalumab) was the fifth medicine to target a key protein found on the body’s immune cells when it won approval last May.

For the current year, companies have more new products waiting in the wings, although the pace of FDA approvals may be tempered by the fact that several drugs that had been expected to be cleared in the first quarter of 2018 were actually approved in 2017.

In Europe, meanwhile, the focus will be on any disruption or delays to the approval process as the European Medicines Agency prepares to relocate from London to Amsterdam as a result of Britain’s decision to leave the European Union.

Source: Reuters; January 2, 2018.

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA